Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Kevin T. Sprott | M | - |
Stablix, Inc.
Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | - |
Carlo Rizzuto | M | 53 |
Stablix, Inc.
Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | - |
Brian Bowman | M | - |
Stablix, Inc.
Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | - |
Tony Kingsley | M | 60 |
Stablix, Inc.
Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | 2 years |
Douglas Williams | M | 66 |
Stablix, Inc.
Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | 1 years |
Ali Behbahani | M | 45 |
Stablix, Inc.
Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | - |
Clare Ozawa | M | 50 |
Stablix, Inc.
Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | - |
Christopher Dinsmore | M | 58 |
Stablix, Inc.
Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | - |
Andrew Phillips | M | - |
Stablix, Inc.
Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | - |
J.C. Lopez | M | - |
Stablix, Inc.
Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 10 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Scott Kanner
- Personal Network